Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penicillamine for Radiosensitization in Recurrent Head and Neck Cancer
NCT06103617Phase 2Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Nov 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of penicillamine in head and neck cancer (HNC), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Objective Response Rate at 1 month. Status: unknown.
02
Drugs
penicillamine
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT06103617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06103617.